Therapeutic avenues for γδ T cells in cancer.

ABSTRACT: γδ T cells are regarded as promising effector lymphocytes for next-generation cancer immunotherapies. In spite of being relatively rare in human peripheral blood, γδ T cells are more abundant in epithelial tissues where many tumors develop, and have been shown to actively participate in anticancer immunity as cytotoxic cells or as "type 1" immune orchestrators. A major asset of γδ T cells for tackling advanced cancers is their independence from antigen presentation via the major histocompatibility complex, which clearly sets them apart from conventional αβ T cells. Here we discuss the main therapeutic strategies based on human γδ T cells. These include antibody-based bispecific engagers and adoptive cell therapies, either focused on the Vδ1⁺ or Vδ2⁺ γδ T-cell subsets,

SUBMITTER: Costa GP 

PROVIDER: S-EPMC10680012 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature